Abstract
This study presents a comprehensive follow-up assessment of a groundbreaking case involving a 43-year-old female patient diagnosed with metastatic Triple Negative Breast Cancer (TNBC). Following a mastectomy and axillary clearance, traditional chemotherapy proved ineffective, leading to a 15-day treatment with glucosodiene a novel metabolic intervention derived from glucose. Initial results demonstrated the restoration of vital functions and the absence of cellular activity. The study explores the efficacy of an individualized treatment plan targeting the Warburg effect in TNBC patients, focusing on inhibiting glucose metabolism with glucosodiene. The F-18 FDG PET/CT scan revealed metabolically active lymph nodes without hypermetabolic lesions indicative of recurrence. Liver and kidney functions, along with hematological parameters, remained within normal ranges, supporting the efficacy of glucosodiene. This case marks the first documented instance worldwide of successful treatment for metastatic TNBC to the bones with glucosodiene. The study underscores the need for further research and refined follow-up protocols in similar cases.